Work for Biohaven Pharmaceutical Holding Company Ltd.?
Claim Your Profile
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Biohaven Pharmaceutical Holding Company Ltd. has reached its limit for free report views.
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Biohaven is a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
